Successful biotech leadership requires a clear decision-making hierarchy. Dr. Bahija Jallal advocates for a framework where patient welfare is paramount, followed by scientific rigor. Financial success is treated as a byproduct of excelling in the first two areas, not the primary goal.
According to Immunocore's CEO, the biggest imminent shift in drug development is AI. The critical need is not for AI to replace scientists, but for a new breed of professionals fluent in both their scientific domain and artificial intelligence. Those who fail to adapt will be left behind.
The most important job of a leader is team building. This means deliberately hiring functional experts who are better than the CEO in their specific fields. A company's success is a direct reflection of the team's collective talent, not the CEO's individual brilliance.
Dr. Bahija Jallal's lifelong pursuit of scientific understanding originated from a childhood tragedy. The death of her father due to a medical error fueled her persistent "why" questions, transforming a desire for answers into a mission to develop better medicines for patients.
A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.
T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.
Immunotherapies can be effective even without causing significant tumor shrinkage. Immunocore's drug KimTrack had a low 5-7% objective response rate (ORR) but demonstrated a massive overall survival (OS) benefit, challenging the reliance on traditional chemotherapy metrics for evaluating modern cancer treatments.